Abbaszade et al., 2021 - Google Patents
Electric and magnetic field applications as alternative or supportive therapy for covid-19Abbaszade et al., 2021
View PDF- Document ID
- 1176359319354067399
- Author
- Abbaszade Z
- Bakirci G
- Haghi M
- Publication year
- Publication venue
- Arch Clin Microbio
External Links
Snippet
Magnetic field, electric field and electric current are part of nature. Therefore, living organisms, likewise viruses, can be affected by physical processes. Therapeutic and supportive effects of electric and magnetic fields are proved in numerous studies on cells …
- 200000000015 coronavirus disease 2019 0 title description 7
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Micro-organisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense
- C12N2760/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses negative-sense ssRNA Viruses negative-sense
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12011588B2 (en) | Inhibiting viral infection using alternating electric fields | |
| Hajam et al. | Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens | |
| Du et al. | Glutathione-capped Ag2S nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding | |
| Sun et al. | Manganese nanodepot augments host immune response against coronavirus | |
| Lee et al. | H7N9 influenza A virus activation of necroptosis in human monocytes links innate and adaptive immune responses | |
| Shi et al. | Astragalus Polysaccharide Protects Astrocytes from Being Infected by HSV‐1 through TLR3/NF‐κB Signaling Pathway | |
| Zhang et al. | p-STAT1 regulates the influenza A virus replication and inflammatory response in vitro and vivo | |
| Abbaszade et al. | Electric and magnetic field applications as alternative or supportive therapy for covid-19 | |
| Ellerhoff et al. | Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus | |
| Bagheri et al. | Does the global outbreak of COVID-19 or other viral diseases threaten the stem cell reservoir inside the body? | |
| CN102021149B (en) | Gene NSI deficit type respiratory syncytial virus and application thereof in treating lung cancer | |
| Han et al. | Antiviral assessment of honeybee (Apis mellifera L.) venom | |
| Abed et al. | Use of nanotechnology in the diagnosis and treatment of coronavirus | |
| Popkov et al. | Do mitochondria have an immune system? | |
| Lv et al. | Broad‐spectrum antiviral effect of MoringaA‐loaded exosomes against IAV by mediating the GCN5‐TFEB‐autolysosome pathway | |
| CN103865890A (en) | Recombinant virus for preventing viral myocarditis as well as vaccine and applications tof recombinant virus | |
| CN113583970B (en) | A medicine for preventing or resisting coronavirus transmission and pathopoiesia, and its preparation method | |
| HK40072629A (en) | Inhibiting viral infection using alternating electric fields | |
| US20250352628A1 (en) | Non-toxic destruction of cancer cells using viral vectored injections | |
| Sharma et al. | Diagnosis and Treatment of COVID-19 Using Nanomedicinal Approach | |
| US20220370585A1 (en) | Curing cancer with viral vectored injections | |
| Manglic et al. | The Effective Therapeutic Strategies to Fight against COVID-19 in India. Research & Reviews: A Journal of Toxicology. 2022; 12 (1): 43–49p | |
| KR20230024280A (en) | Compositions and methods for treating viral infections (COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS) | |
| Bolduc et al. | PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines | |
| Kumar et al. | A REVIEW ON DIFFERENT PREVENTION AND TREATMENT TECHNOLOGY USED FOR THE CURING OF VIRAL INFECTION |